RESUMO
Levodopa-induced heavy dyskinesia was modeled in rats with severe hemiparkinsonian syndrome induced by injection of 6-hydroxydopamine in the left medial forebrain bundle. It is established that the antidyskinetic effect of the injectable dosage form of a new antiparkinsonian drug hemantane (5 mg/kg) after a single intravenous administration is weaker than that of the most effective in clinical practice antidyskinetic drug amantadine (20 mg/kg). However, after five days of treatment, the effect of hemantane injections exceeded that of amantadine.
Assuntos
Adamantano/análogos & derivados , Adrenérgicos/efeitos adversos , Antiparkinsonianos/efeitos adversos , Discinesia Induzida por Medicamentos/fisiopatologia , Levodopa/efeitos adversos , Oxidopamina/efeitos adversos , Transtornos Parkinsonianos/fisiopatologia , Adamantano/farmacologia , Adrenérgicos/farmacologia , Animais , Antiparkinsonianos/farmacologia , Discinesia Induzida por Medicamentos/tratamento farmacológico , Levodopa/farmacologia , Masculino , Oxidopamina/farmacologia , Transtornos Parkinsonianos/induzido quimicamente , Transtornos Parkinsonianos/tratamento farmacológico , RatosRESUMO
A single intraperitoneal injection of MPTP neurotoxin (30 mg/kg) in C57BL/6 mice causes desynchronization of EEG with a decrease of theta-1 activity and a growth of beta activity in the interval of 15-30 Hz. Subchronic administration of the new antiparkinsonian drug hemantane (injection form) in a dose of 10 mg/kg makes the power of MPTP-induced beta oscillations less pronounced and leads to its reliable decrease within 24 h. This effect of hemantane administration was manifested during the entire period of observations.
Assuntos
Adamantano/análogos & derivados , Ritmo beta/efeitos dos fármacos , Intoxicação por MPTP/fisiopatologia , Doença de Parkinson Secundária/fisiopatologia , Ritmo Teta/efeitos dos fármacos , Adamantano/farmacologia , Animais , Intoxicação por MPTP/tratamento farmacológico , Masculino , Camundongos , Doença de Parkinson Secundária/tratamento farmacológico , Fatores de TempoRESUMO
Effects of the novel antiparkinsonian drug himantane and amantadin were studied in rats with intracerebral posttraumatic hematoma. Drugs were administered first at 3.5 hours after surgery and then for 4 consecutive days. Effects were registered on days 1, 3, 7 and 14 after surgery. It was shown that both drugs significantly decreased mortality and improved motor activity, exploratory behavior and memory. Amantadin was more effective in tests for motor activity and exploratory behavior. Himantane 5 mg/kg i.p demonstrated the more pronounced activity in restoring memory. The results obtained testify for neuroprotective properties of the novel antiparkinsonian drug himantane.
Assuntos
Adamantano/análogos & derivados , Amantadina/uso terapêutico , Antiparkinsonianos/uso terapêutico , Hemorragia Cerebral Traumática/tratamento farmacológico , Adamantano/uso terapêutico , Animais , Hemorragia Cerebral Traumática/psicologia , Hemorragia Cerebral Traumática/reabilitação , Modelos Animais de Doenças , Comportamento Exploratório/efeitos dos fármacos , Masculino , Memória/efeitos dos fármacos , Tono Muscular/efeitos dos fármacos , RatosRESUMO
Chronic administration of levodopa and benserazide (10 and 15 mg/kg, respectively) cause the development of dyskinesia in rats with model parkinsonian syndrome induced by injection of 6-hydroxydopamine in left substantia nigra. The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia. Chronic administration of levodopa and benserazide together with hemantane (10 mg/kg) slows down the development and decreases the magnitude of levodopa-induced abnormal involuntary movements as measured for limb, orolingual and rotatory movements.
